Drug and trial acronym | Number of publications (abstracts) | Interventions compared | Type of patients included | Timing of primary end point | Primary end point | Risk of bias assessment |
---|---|---|---|---|---|---|
MTX (MIPA)14 | 1 (0) | MTX 15 m/week, PBO | DMARD or NSAIDs failure, but MTX naive | 24W | PsARC | Low |
MTX vs Ciclosporine15 | 1 (0) | ETA+MTX, ETA+CYC | DMARD failure | 24W | NA | Unclear |
Leflunomide16 | 1 (0) | LEF, MTX | NA | 24W | PsARC | High |
Golimumab (GO-REVEAL)17–21 | 5 (0) | GOL 100 mg, GOL 50 mg, PBO | DMARD or NSAIDs failure | 14W+24W (coprimary end point) | ACR20+change in radiographic score | Low |
Certolizumab pegol (RAPID-PsA)22–27 | 4 (2) | CZP 400 mg, CZP 200 mg, PBO | DMARD or TNFi failure | 12W | ACR20 | Low |
Infliximab (RESPOND)28 | 1 (0) | IFX 5 mg/kg+MTX 15 mg, MTX 15mg | DMARD or NSAIDs failure, but MTX naive | 16W | ACR20 | High |
Adalimumab (ADEPT)29 | 1 (0) | ADA 40 mg, PBO | NSAIDs failure | 12W+24W (coprimary end point) | ACR20+change in radiographic score | Unclear |
Etanercept (PRESTA)30 31 32 33 | 4 (0) | ETA 50 mg 2×week, ETA 50 mg 1×week | DMARD or NSAIDs failure | 12W | Physician's global assessment of psoriasis | Low |
UST | ||||||
—PSUMMIT 11 45 | 1 (1) | UST 90 mg, UST 45 mg, PBO | DMARD or NSAIDs failure | 24W | ACR20 | Low |
—PSUMMIT 22 34 | 2 (0) | DMARD or NSAIDs or TNFi failure | 24W | ACR20 | Low | |
SEC | ||||||
—FUTURE 15 | 1 (0) | SEC 150 mg, SEC 75 mg, PBO | DMARD or NSAIDs or TNFi failure | 24W | ACR20 | Low |
—FUTURE 24 | 1 (0) | SEC 300 mg, SEC 150 mg, SEC 75 mg, PBO | DMARD or NSAIDs or TNFi failure | 24W | ACR20 | Low |
APR | ||||||
—PALACE 13 35–37 | 1 (3) | APR 30 mg, APR 20 mg, PBO | DMARD or TNFi failure (<10%) | 16W | ACR20 | Unclear |
—PALACE 238 | 0 (1) | DMARD or TNFi failure | 16W | ACR20 | NA* | |
—PALACE 339 | 0 (1) | DMARD or TNFi failure | 16W | ACR20 | NA* | |
—PALACE 440–43 | 0 (4) | DMARD or TNFi failure | 16W | ACR20 | NA* | |
Strategy trial (TICOPA)44 | 1 (0) | Tight control, standard care | DMARD naive | 48W | ACR20 | Low |
No trials were available for glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs).
†25 publications and 12 abstracts have been included.
ACR20, American College of Rheumatology 20% improvement; ADA, adalimumab; ADEPT, adalimumab effectiveness in psoriatic arthritis trial; APR, apremilast; CYC, ciclosporine; CZP, certolizumab pegol; DMARD, disease-modifying antirheumatic drug; ETA, etanercept; GOL, golimumab; IFX, infliximab; LEF, leflunomide; MIPA, methotrexate in psoriatic arthritis; MTX, methotrexate; NA*, not assessed, risk of bias assessment not possible as only abstract data; NA, not available; NSAID, non-steroidal anti-inflammatory drug; PALACE, psoriatic arthritis long-term assessment of clinical efficacy; PBO, placebo; PRESTA, psoriasis randomized etanercept study in subjects with psoriatic arthritis; PsA, psoriatic arthritis; PsARC, PsA response criteria; RCTs, randomised controlled trials; SEC, secukinumab; TICOPA, tight control of psoriatic arthritis; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab.